Myocardial Gene Expression of Angiogenic Factors in Human Chronic Ischemic Myocardium: Influence of Acute Ischemia/Cardioplegia and Reperfusion
- 5 April 2006
- journal article
- Published by Wiley in Microcirculation
- Vol. 13 (3) , 187-197
Abstract
Objective: Angiogenic therapies in animals have demonstrated the development of new blood vessels within ischemic myocardium. However, results from clinical protein and gene angiogenic trials have been less impressive. The present study aimed to investigate the expression of angiogenic genes in human chronic ischemic myocardium and the influence of acute ischemia/cardioplegia and reperfusion on their expression.Methods: Myocardial biopsies were taken from chronic ischemic and nonischemic myocardium in 15 patients with stable angina pectoris during coronary bypass surgery. Tissue samples were evaluated by oligonucleotide microarray and quantitative real‐time PCR for the expression of angiogenic factors.Results: There was identical baseline expression of VEGF‐A and VEGF‐C mRNA in chronic ischemic myocardium compared with nonischemic myocardium. Reperfusion increased the gene expression of VEGF‐A and VEGF‐C mRNA both in nonischemic and ischemic myocardium. VEGF‐A protein was detected mainly in the extracellular matrix around the cardiomyocytes in ischemic myocardium.Conclusion: These data suggest that the nonconclusive VEGF gene therapy trials chronic coronary artery disease was not due to a preexisting upregulation of VEGF in chronic ischemic myocardium. There might be room for further therapeutic angiogenesis in chronic ischemic myocardium.Keywords
This publication has 32 references indexed in Scilit:
- Direct intramyocardial plasmid vascular endothelial growth factor-A165gene therapy in patients with stable severe angina pectorisJACC, 2005
- Therapeutic Angiogenesis in Ischemic Heart Disease: Gene or Recombinant Vascular Growth Factor Protein Therapy?Current Gene Therapy, 2003
- The VIVA TrialCirculation, 2003
- Phase 1/2 Placebo-Controlled, Double-Blind, Dose-Escalating Trial of Myocardial Vascular Endothelial Growth Factor 2 Gene Transfer by Catheter Delivery in Patients With Chronic Myocardial IschemiaCirculation, 2002
- Angiogenic Gene Therapy (AGENT) Trial in Patients With Stable Angina PectorisCirculation, 2002
- Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2Circulation, 2002
- Myocardial gene therapyNature, 2002
- Randomized, Single-Blind, Placebo-Controlled Pilot Study of Catheter-Based Myocardial Gene Transfer for Therapeutic Angiogenesis Using Left Ventricular Electromechanical Mapping in Patients With Chronic Myocardial IschemiaCirculation, 2001
- Vascular Growth Factor and Gene Therapy to Induce New Vessels in the Ischemic Myocardium. Therapeutic AngiogenesisScandinavian Cardiovascular Journal, 2001
- VEGF contributes to postnatal neovascularization by mobilizing bone marrow‐derived endothelial progenitor cellsThe EMBO Journal, 1999